Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.30 and traded as low as $0.27. Northwest Biotherapeutics shares last traded at $0.27, with a volume of 2,896,227 shares changing hands.
Northwest Biotherapeutics Stock Performance
The firm has a market cap of $360.16 million, a PE ratio of -3.38 and a beta of -0.50. The company’s 50-day simple moving average is $0.28 and its two-hundred day simple moving average is $0.30.
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.02) earnings per share for the quarter. The business had revenue of $0.36 million during the quarter.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
See Also
- Five stocks we like better than Northwest Biotherapeutics
- What is the S&P/TSX Index?
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Profitably Trade Stocks at 52-Week Highs
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- What Are Dividends? Buy the Best Dividend Stocks
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
